BioNote (377740.KS) Stock Price

BioNote Price

CLOSED
4,715.00KRW+145.00 (+3.12 %)
Market closed

Revenue has compounded at 20.7% per year over the past 5 years to 102.78 B KRW. Earnings per share have grown at 21.8% per year over the last 5 years. BioNote's net margin stands at 53.8%, down from 83.6% several years earlier. BioNote currently offers a dividend yield of about 4.24%. The payout ratio is around 37% of earnings. Analysts set a median price target of 5,814.00 KRW, implying 23.3% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 10% above its 52-week low.

BioNote stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of BioNote over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioNote stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioNote's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

BioNote Stock Price History
DateBioNote Price
7/10/20264,715.00 KRW
7/9/20264,570.00 KRW
7/8/20264,605.00 KRW
7/7/20264,670.00 KRW
7/6/20264,675.00 KRW
7/3/20264,605.00 KRW
7/2/20264,600.00 KRW
7/1/20264,610.00 KRW
6/30/20264,510.00 KRW
6/29/20264,480.00 KRW
6/26/20264,300.00 KRW
6/25/20264,475.00 KRW
6/24/20264,350.00 KRW
6/23/20264,375.00 KRW
6/22/20264,590.00 KRW
6/19/20264,640.00 KRW
6/18/20264,630.00 KRW
6/17/20264,750.00 KRW
6/16/20264,880.00 KRW
6/15/20264,955.00 KRW
6/12/20264,870.00 KRW
6/11/20264,810.00 KRW
6/10/20264,720.00 KRW
6/9/20264,650.00 KRW
6/8/20264,520.00 KRW
6/5/20264,690.00 KRW
6/4/20264,715.00 KRW
6/2/20264,770.00 KRW
6/1/20264,755.00 KRW
5/29/20264,890.00 KRW
5/28/20264,950.00 KRW
5/27/20265,000.00 KRW
5/26/20265,050.00 KRW
5/22/20265,120.00 KRW
5/21/20265,010.00 KRW
5/20/20264,995.00 KRW
5/19/20264,990.00 KRW
5/18/20265,030.00 KRW
5/15/20264,975.00 KRW
5/14/20265,150.00 KRW
5/13/20265,040.00 KRW
5/12/20264,880.00 KRW
5/11/20264,940.00 KRW
5/8/20264,985.00 KRW
5/7/20264,985.00 KRW
5/6/20265,020.00 KRW
5/4/20265,050.00 KRW
4/30/20265,110.00 KRW
4/29/20265,130.00 KRW
4/28/20265,170.00 KRW
4/27/20265,170.00 KRW
4/24/20265,190.00 KRW
4/23/20265,130.00 KRW
4/22/20265,070.00 KRW
4/21/20265,130.00 KRW
4/20/20265,140.00 KRW
4/17/20265,280.00 KRW
4/16/20265,120.00 KRW
4/15/20265,040.00 KRW
4/14/20264,970.00 KRW
4/13/20264,965.00 KRW
4/10/20264,965.00 KRW
4/9/20264,930.00 KRW
4/8/20264,920.00 KRW
4/7/20264,850.00 KRW
4/6/20264,940.00 KRW
4/3/20265,020.00 KRW
4/2/20264,995.00 KRW
4/1/20265,170.00 KRW
3/31/20265,060.00 KRW
3/30/20265,290.00 KRW
3/27/20265,480.00 KRW
3/26/20265,470.00 KRW
3/25/20265,490.00 KRW
3/24/20265,380.00 KRW
3/23/20265,330.00 KRW
3/20/20265,440.00 KRW
3/19/20265,340.00 KRW
3/18/20265,400.00 KRW
3/17/20265,370.00 KRW
3/16/20265,360.00 KRW
3/13/20265,440.00 KRW
3/12/20265,370.00 KRW
3/11/20265,410.00 KRW
3/10/20265,340.00 KRW
3/9/20265,330.00 KRW
3/6/20265,460.00 KRW
3/5/20265,500.00 KRW
2/26/20265,670.00 KRW
2/25/20266,200.00 KRW
2/24/20266,230.00 KRW
2/23/20266,050.00 KRW
2/20/20265,850.00 KRW
2/19/20265,830.00 KRW
2/13/20265,800.00 KRW
2/12/20265,800.00 KRW
2/11/20265,740.00 KRW
2/10/20265,720.00 KRW
2/9/20265,650.00 KRW
2/6/20265,540.00 KRW
2/5/20265,660.00 KRW
2/4/20265,800.00 KRW
2/3/20265,770.00 KRW
2/2/20265,710.00 KRW
1/30/20265,840.00 KRW
1/29/20265,560.00 KRW
1/28/20265,470.00 KRW
1/27/20265,530.00 KRW
1/26/20265,530.00 KRW
1/23/20265,290.00 KRW
1/22/20265,140.00 KRW
1/21/20265,100.00 KRW
1/20/20265,180.00 KRW
1/19/20265,100.00 KRW
1/16/20265,190.00 KRW
1/15/20265,200.00 KRW
1/14/20265,190.00 KRW
1/13/20265,200.00 KRW
1/12/20265,250.00 KRW
1/9/20265,360.00 KRW
1/8/20265,430.00 KRW
1/7/20265,520.00 KRW
1/6/20265,510.00 KRW
1/5/20265,500.00 KRW
1/2/20265,520.00 KRW
12/30/20255,470.00 KRW
12/29/20255,530.00 KRW
12/26/20255,620.00 KRW
12/24/20255,610.00 KRW
12/23/20255,600.00 KRW
12/22/20255,640.00 KRW
12/19/20255,650.00 KRW
12/18/20255,580.00 KRW
12/17/20255,620.00 KRW
12/16/20255,620.00 KRW
12/15/20255,600.00 KRW
12/12/20255,610.00 KRW
12/11/20255,650.00 KRW
12/10/20255,590.00 KRW
12/9/20255,690.00 KRW
12/8/20255,560.00 KRW
12/5/20255,640.00 KRW
12/4/20255,590.00 KRW
12/3/20255,630.00 KRW
12/2/20255,650.00 KRW
12/1/20255,620.00 KRW
11/28/20255,640.00 KRW
11/27/20255,570.00 KRW
11/26/20255,570.00 KRW
11/25/20255,500.00 KRW
11/24/20255,530.00 KRW
11/21/20255,490.00 KRW
11/20/20255,590.00 KRW
11/19/20255,500.00 KRW
11/18/20255,450.00 KRW
11/17/20255,600.00 KRW
11/14/20255,710.00 KRW
11/13/20255,770.00 KRW
11/12/20255,710.00 KRW
11/11/20255,620.00 KRW
11/10/20255,660.00 KRW
11/7/20255,590.00 KRW
11/6/20255,530.00 KRW
11/5/20255,560.00 KRW
11/4/20255,530.00 KRW
11/3/20255,390.00 KRW
10/31/20255,510.00 KRW
10/30/20255,520.00 KRW
10/29/20255,510.00 KRW
10/28/20255,500.00 KRW
10/27/20255,520.00 KRW
10/24/20255,490.00 KRW
10/23/20255,570.00 KRW
10/22/20255,560.00 KRW
10/21/20255,490.00 KRW
10/20/20255,550.00 KRW
10/17/20255,640.00 KRW
10/16/20255,740.00 KRW
10/15/20255,770.00 KRW
10/14/20255,670.00 KRW
10/13/20255,840.00 KRW
10/10/20255,820.00 KRW
10/2/20255,800.00 KRW
10/1/20255,800.00 KRW
9/30/20255,800.00 KRW
9/29/20255,910.00 KRW
9/26/20255,840.00 KRW
9/25/20255,910.00 KRW
9/24/20256,000.00 KRW
9/23/20256,060.00 KRW
9/22/20256,080.00 KRW
9/19/20256,210.00 KRW
9/18/20256,120.00 KRW
9/17/20256,100.00 KRW
9/16/20256,100.00 KRW
9/15/20256,140.00 KRW
9/12/20256,100.00 KRW
9/11/20256,040.00 KRW
9/10/20256,060.00 KRW
9/9/20256,190.00 KRW
9/8/20256,100.00 KRW
9/5/20255,670.00 KRW
9/4/20255,640.00 KRW
9/3/20255,570.00 KRW
9/2/20255,620.00 KRW
9/1/20255,510.00 KRW
8/29/20255,690.00 KRW
8/28/20255,700.00 KRW
8/27/20255,620.00 KRW
8/26/20255,570.00 KRW
8/25/20255,610.00 KRW
8/22/20255,800.00 KRW
8/21/20255,740.00 KRW
8/20/20255,700.00 KRW
8/19/20255,590.00 KRW
8/18/20255,520.00 KRW
8/14/20255,400.00 KRW
8/13/20255,270.00 KRW
8/12/20255,260.00 KRW
8/11/20255,230.00 KRW
8/8/20255,270.00 KRW
8/7/20255,220.00 KRW
8/6/20255,250.00 KRW
8/5/20255,210.00 KRW
8/4/20255,190.00 KRW
8/1/20255,140.00 KRW
7/31/20255,240.00 KRW
7/30/20255,260.00 KRW
7/29/20255,220.00 KRW
7/28/20255,180.00 KRW
7/25/20255,270.00 KRW
7/24/20255,240.00 KRW
7/23/20255,290.00 KRW
7/22/20255,280.00 KRW
7/21/20255,280.00 KRW
7/18/20255,300.00 KRW
7/17/20255,310.00 KRW
7/16/20255,290.00 KRW
7/15/20255,340.00 KRW
7/14/20255,290.00 KRW
Access this data via the Eulerpool API
Get Free API Key

BioNote Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
40.05 B KRW
9.93 B KRW
20.61 B KRW
Jan 1, 2020
631.50 B KRW
558.03 B KRW
528.23 B KRW
Jan 1, 2021
622.36 B KRW
468.75 B KRW
676.60 B KRW
Jan 1, 2022
479.66 B KRW
295.41 B KRW
307.80 B KRW
Jan 1, 2023
90.08 B KRW
-47.04 B KRW
-20.50 B KRW
Jan 1, 2024
102.78 B KRW
12.22 B KRW
55.26 B KRW
Jan 1, 2025 (e)
151.97 B KRW
13.30 B KRW
17.30 B KRW
Jan 1, 2026 (e)
196.62 B KRW
23.67 B KRW
31.74 B KRW

BioNote Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 12, 2026, 7:40 PM
 
REVENUEB KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB KRW
NET INCOMEB KRW
NET INCOME GROWTH%
DIV.KRW
DIV. GROWTH%
SHARESM
2019202020212022202320242025e2026e
40.05631.51622.36479.6690.08102.78151.97196.62
–1,476.91-1.45-22.93-81.2214.1047.8629.38
46.7591.7882.2871.04-12.8449.8549.8549.85
18.72579.58512.06340.73-11.5751.2475.7698.02
20.61528.23676.60307.80-20.5055.2617.3031.74
–2,462.7328.09-54.51-106.66-369.62-68.7083.46
–––490.00490.00200.00200.00200.00
–––––-59.18––
101.88101.8893.69101.88101.98101.96101.96101.96
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales BioNote generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioNote retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioNote's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares BioNote has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioNote's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

BioNote stock margins

The BioNote margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioNote. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioNote.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
46.75 %
24.79 %
51.47 %
Jan 1, 2020
91.78 %
88.37 %
83.65 %
Jan 1, 2021
82.28 %
75.32 %
108.72 %
Jan 1, 2022
71.04 %
61.59 %
64.17 %
Jan 1, 2023
-12.84 %
-52.22 %
-22.75 %
Jan 1, 2024
49.85 %
11.88 %
53.77 %
Jan 1, 2025 (e)
49.85 %
8.75 %
11.38 %
Jan 1, 2026 (e)
49.85 %
12.04 %
16.14 %

BioNote Stock Revenue, EBIT, Earnings per Share

The BioNote earnings per share therefore indicates how much revenue BioNote has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
393.10 KRW
97.45 KRW
202.33 KRW
Jan 1, 2020
6,198.75 KRW
5,477.55 KRW
5,185.01 KRW
Jan 1, 2021
6,642.68 KRW
5,003.16 KRW
7,221.67 KRW
Jan 1, 2022
4,708.24 KRW
2,899.69 KRW
3,021.30 KRW
Jan 1, 2023
883.34 KRW
-461.29 KRW
-200.99 KRW
Jan 1, 2024
1,008.06 KRW
119.81 KRW
542.00 KRW
Jan 1, 2025 (e)
1,490.55 KRW
130.44 KRW
169.67 KRW
Jan 1, 2026 (e)
1,928.41 KRW
232.11 KRW
311.28 KRW

BioNote business model & stock analysis

BioNote Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

BioNote historical P/E ratio, EBIT multiple, and P/S ratio

BioNote annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

BioNote shares outstanding

The number of shares of BioNote was 101.96 M in 2025. This indicates how many shares BioNote is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
101.88 M Stocks
Jan 1, 2020
101.88 M Stocks
Jan 1, 2021
93.69 M Stocks
Jan 1, 2022
101.88 M Stocks
Jan 1, 2023
101.98 M Stocks
Jan 1, 2024
101.96 M Stocks
Jan 1, 2025 (e)
101.96 M Stocks
Jan 1, 2026 (e)
101.96 M Stocks

BioNote Dividend History

5 years of dividend payments

YearAnnual DividendYoY ChangePayments
2026229.00KRWYTD—1×
Mar 30, 2026229.00KRW↑ 14.5%1/1
2025200.00KRW 0.0%1×
Mar 28, 2025200.00KRW 0.0%1/1
2024200.00KRW↓ 59.2%1×
2023490.00KRW 0.0%—
2022490.00KRW—1×

BioNote dividend history and estimates

In 2025, BioNote paid a dividend amounting to 200.00 KRW. Dividend means that BioNote distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2022 (e)
0.00 KRW
490.00 KRW
Jan 1, 2023
490.00 KRW
0.00 KRW
Jan 1, 2024
200.00 KRW
0.00 KRW
Jan 1, 2025
200.00 KRW
0.00 KRW
Jan 1, 2026 (e)
0.00 KRW
200.00 KRW

BioNote dividend payout ratio

In 2025, BioNote had a payout ratio of 117.87%. The payout ratio indicates the percentage of the company's profits that BioNote distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2019
26.56 %
Jan 1, 2020
26.56 %
Jan 1, 2021
26.56 %
Jan 1, 2022
16.22 %
Jan 1, 2023
26.56 %
Jan 1, 2024
36.90 %
Jan 1, 2025 (e)
117.87 %
Jan 1, 2026 (e)
64.25 %

Current BioNote forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy80.00 % (4)
Hold20.00 % (1)
Sell0.00 % (0)
12M Price Target
5,814.00
Last Price
4,715.00
Currency
KRW
12M Return Potential
23.31 %
LTM Return
0 %

BioNote shareholder structure

% Name
35.02608%
Jo (Yeong Sik)
Jo (Yeong Sik)
16.40852%
Jo (Hye Im)
Jo (Hye Im)
15.23760%
SDB Investment Co., Ltd.
SDB Investment Co., Ltd.
5.93930%
Intervest Bio Healthcare Investment Association
Intervest Bio Healthcare Investment Association
5.69134%
InterVest Co., Ltd.
InterVest Co., Ltd.
3.09931%
Ha (Geon U)
Ha (Geon U)

BioNote Executives and Management Board

GH

Geon Wu Han

Chief Executive Officer

Frequently asked questions about BioNote

Analysts currently set an average price target of 5,814.00 KRW for the BioNote stock (median: 5,814.00 KRW), implying +23.3 % versus the latest price. The consensus is based on 5 analyst ratings.

BioNote Analyst Price Targets 2026

All fundamentals and in-depth analysis of BioNote

Our stock analysis for BioNote stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioNote. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

BioNote Stock
BioNote Revenue→
BioNote Stock
BioNote Net Income→
BioNote Stock
BioNote P/E→
BioNote Stock
BioNote P/S→
BioNote Stock
BioNote EBIT→
BioNote Stock
BioNote Dividend→
BioNote Stock
BioNote Directors Dealings→
BioNote Stock
BioNote Stocks→
BioNote Stock
BioNote Market capitalization→
BioNote Stock
BioNote Debt→
BioNote Stock
BioNote Liabilities→
BioNote Stock
BioNote Equity→
BioNote Stock
BioNote AAQS→
BioNote Stock
BioNote Employees→
BioNote Stock
BioNote ROE→
BioNote Stock
BioNote ROA→
BioNote Stock
BioNote ROCE→
BioNote Stock
BioNote News→
BioNote Stock
BioNote Analyst Price Targets→

Health Stocks

Bionovate TechnologiesBionimeBiontechBionik LaboratoriesBioNxt SolutionsBionetBiophytisBioneerBioporto A/SBionano GenomicsBioptik TechnologyBiomxAll Stocks A–Z →